Chronic obstructive pulmonary disease (COPD) is common in patients undergoing percutaneous coronary intervention (PCI), but the impact of COPD on outcomes after PCI has received limited attention. Consecutive patients with coronary heart disease (n = 5155) undergoing PCI were enrolled in this study; 645 patients (73% men) aged 68.4 ± 13.2 years had COPD and 4510 patients (71% men) aged 64.7 ± 12.1 years did not. During the in-hospital period after PCI, the patients with COPD experienced a significantly higher incidence of angina (P < .001), arrhythmias (P < .001), and composite major adverse cardiac events (MACEs; P < .001) and longer hospital stay (P < .001) than those without COPD. Additionally, severity of COPD (measured by pulmonary function tests) was associated with increased composite MACE (P < .001) and hospital stay (P < .001) after PCI. In conclusion, COPD is associated with significantly increased composite MACE and hospital stay in patients after PCI. Increasing severity of COPD is associated with increased composite MACE and hospital stay after PCI.
HoleDJWattGCDavey-SmithGHartCLGillisCRHawthorneVM. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ. 1996;313:711–715.
2.
FalkJAKadievSCrinerGJScharfSMMinaiOADiazP. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(4):543–548.
3.
EngströmGHedbladBValindSJanzonL. Asymptomatic leg and carotid atherosclerosis in smokers is related to degree of ventilatory capacity: longitudinal and cross-sectional results from ‘Men born in 1914’, Sweden. Atherosclerosis. 2001;155(1):237–243.
4.
EngströmGLindPHedbladB. Lung function and cardiovascular risk: relationship with inflammation-sensitive plasma proteins. Circulation. 2002;106(20):2555–2560.
5.
FilsoufiFRahmanianPBCastilloJGChikweJKiniASAdamsDH. Results and predictors of early and late outcome of coronary artery bypass grafting in patients with severely depressed left ventricular function. Ann Thorac Surg. 2007;84 (3):808–816.
6.
NishiyamaKMorimotoTFurukawaY. Chronic obstructive pulmonary disease—an independent risk factor for long-term cardiac and cardiovascular mortality in patients with ischemic heart disease. Int J Cardiol. 2010;143(2):178–183.
7.
SamuelsLEKaufmanMSMorrisRJPromisloffRBrockmanSK. Coronary artery bypass grafting in patients with COPD. Chest. 1998;113(4):878–882.
8.
PauwelsRABuistASCalverleyPMJenkinsCRHurdSS, GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001;163(5):1256–1276.
9.
MorcosSK.Contrast medium-induced nephrotoxicity. In: DawsonP, ed. Textbook of Contrast Media. Oxford, UK: Isis Medical Media Ltd; 1999.
10.
MorcosSKThomsenHSWebbJA. Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol. 1999;9(8):1602–1613.
11.
RabeKFHurdSAnzuetoA. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532–55.
12.
KullerLHOckeneJKTownsendMBrownerWMeilahnEWentworthDN. The epidemiology of pulmonary function and COPD mortality in the multiple risk factor intervention trial. Am Rev Respir Dis. 1989;140(3 Pt 2):S76–S78.
13.
SelvarajCLGurmHSGuptaREllisSGBhattDL. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2005;96(6):756–759.
14.
BergerJSSanbornTAShermanWBrownDL. Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention. Am J Cardiol. 2004;94(5):649–651.
15.
KonecnyTSomersKOrbanM. Interactions between COPD and outcomes after percutaneous coronary intervention. Chest. 2010;138(3):621–627.
16.
DevDWallaceESankaranR. Value of C-reactive protein measurements in exacerbations of chronic obstructive pulmonary disease. Respir Med. 1998;92(4):664–667.
17.
AndreasSAnkerSDScanlonPDSomersVK. Neurohumoral activation as a link to manifestations of chronic lung disease. Chest. 2005;128(5):3618–3624.
18.
HeindlSLehnertMCriéeCPHasenfussGAndreasS. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001;164(4):597–601.
19.
HjalmarsenAAasebøUAleksandersenGJordeR. Cardiovascular responses to tests for autonomic dysfunction in patients with chronic obstructive pulmonary disease with and without continuous long-term oxygen therapy. J Auton Nerv Syst. 1996;60(3):169–174.
20.
PatakasDLouridasGKakavelasE. Reduced baroreceptor sensitivity in patients with chronic obstructive pulmonary disease. Thorax. 1982;37(4):292–295.
21.
CollopN. Sleep and sleep disorders in chronic obstructive pulmonary disease. Respiration. 2010;80(1):78–86.
22.
KostapanosMSElisafMSMikhailidisDP. Obstructive Sleep Apnea and Cardiovascular Risk: Is Metabolic Syndrome the Link? [published online February 8, 2012]. Angiology. 2012. doi:10.1177/0003319711436077
23.
BarrRGMesia-VelaSAustinJH. Impaired flow mediated dilation is associated with low pulmonary function and emphysema in ex-smokers: the Emphysema and Cancer Action Project (EMCAP) Study. Am J Respir Crit Care Med. 2007;176(12):1200–1207.
24.
McAllisterDAMaclayJDMillsNL. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176(12):1208–1214.
25.
ZarubinaEGMishinaEAOsadchukMA. The role of endothelial dysfunction in the pathogenesis of combined cardiopulmonary diseases. Klin Med (Mosk). 2006;84(5):31–34.
26.
ParkBHParkMSChangJ. Chronic obstructive pulmonary disease and metabolic syndrome: a nationwide survey in Korea. Int J Tuberc Lung Dis. 2012;16(5):694–700.
27.
MarquisKMaltaisFDuguayV. The metabolic syndrome in patients withchronic obstructive pulmonary disease. J Cardiopulm Rehabil. 2005;25(4):226–232. discussion 233-234.
28.
WakabayashiKGonzalezMADelhayeC. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am J Cardiol. 2010;106(3):305–309.
29.
MacneeWMaclayJMcAllisterD. Cardiovascular injury and repair in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5(8):824–833.
30.
CurkendallSMDeLuiseCJonesJK. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006;16(1):63–70.
31.
KarhaJBavryAARajagopalVHendersonMREllisSGBrenerSJ. Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent. Am J Cardiol. 2006;98(5):616–618.
32.
JurewitzDLPessegueiroAZimmerRBhatiaRTobisJLeeMS. Preprocedural white blood cell count as a predictor of death and major adverse cardiac events in patients undergoing percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2009;21(5):202–206.
33.
BertomeuVCorderoAQuilesJMazonPAznarJBuenoH. Control of risk factors in and treatment of patients with coronary heart disease: the TRECE study. Rev Esp Cardiol. 2009;62(7):807–811.
